\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Events

William Blair Biotech Focus Conference
 August 6, 2020
 1:00pm - 1:45pm EDT
 Listen to the Webcast

Cardiff Oncology CRO, Dr. Mark Erlander, will participate in a fireside chat at the William Blair Biotech Focus Conference on Thursday, August 6, 2020 at 1:00 pm ET (10:00 am PT).